Evaluation of new biomarkers in stage III and IV endometriosis
Objective To investigate the efficacy of new endometriosis biomarkers in diagnosis and treatment.Methods Thirty women with Stage III-IV endometriosis who were given an indication for surgery and 49 control patients were compared. Preoperative and postoperative serum levels of Annexin A5 (ANXA5), sol...
Furkejuvvon:
| Váldodahkkit: | , , , , , |
|---|---|
| Materiálatiipa: | Girji |
| Almmustuhtton: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
| Fáttát: | |
| Liŋkkat: | Connect to this object online. |
| Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
| Čoahkkáigeassu: | Objective To investigate the efficacy of new endometriosis biomarkers in diagnosis and treatment.Methods Thirty women with Stage III-IV endometriosis who were given an indication for surgery and 49 control patients were compared. Preoperative and postoperative serum levels of Annexin A5 (ANXA5), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), soluble vascular cell adhesion molecule-1 (sVCAM-1), vascular endothelial growth factors (VEGF) and Ca-125 measurements were compared.Results AUCs of ANXA5, sICAM-1, IL-6, TNF-α, VCAM-1, VEGF biomarkers were not found to be significant in diagnosing endometriosis when evaluated alone (p > 0.05). Only the AUC of the Ca-125 biomarker values were found to be significant with 73% sensitivity and 98% specificity (p < 0.001). However, when Ca-125 and ANXA5 were evaluated together, it was concluded that the diagnosis of endometriosis could be made with 73% sensitivity and 100% specificity.Conclusion When Ca-125 and ANXA5 are evaluated together, it seems to be more valuable than Ca-125 alone in diagnosing endometriosis. |
|---|---|
| Fuomášahttimat: | 10.1080/09513590.2023.2217290 1473-0766 0951-3590 |